Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
Authors:
- Vu H. DuongVDVu H. Duong
- Rami S. KomrokjiRKRami S. Komrokji
- Alan F. ListALAlan F. List
- 30 January 2012
- journal article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 3 (2) , 105-116
Abstract
Myelodysplastic syndrome (MDS) with del(5q) is a unique hematopoietic stem cell disease that typically follows an indolent course and demonstrates particular sensitivity to lenalidomide, a second-generation immunomodulatory agent. Early trials demonstrated rapid and durable responses leading to US Food and Drug Administration (FDA) approval in 2005. Definitive confirmatory evidence from a large phase III trial was recently published. Other recent advances include a better understanding of the pathogenesis of disease including haplodeficiency of several candidate genes, and elucidation of the lenalidomide-specific effect on two phosphatases ultimately leading to p53 degradation in the erythroid progenitors and cell cycle arrest in earlier myeloid progenitors. In this review, we describe the pathogenesis of MDS with del(5q), summarize the major clinical studies establishing the activity of lenalidomide in this population, discuss commonly encountered adverse events, and shed light on practical uses of this agent in the clinic.Keywords
This publication has 59 references indexed in Scilit:
- WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutationsLeukemia, 2010
- FISH and SNP-A karyotyping in myelodysplastic syndromes: Improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q)Leukemia Research, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotypeNature Medicine, 2009
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideProceedings of the National Academy of Sciences, 2009
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patientsProceedings of the National Academy of Sciences, 2007
- Ribosomal Protein S24 Gene Is Mutated in Diamond-Blackfan AnemiaThe American Journal of Human Genetics, 2006